SQZ Biotechnologies (SQZB)
(Delayed Data from OTC)
$0.04 USD
0.00 (-6.98%)
Updated Sep 18, 2024 09:30 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for SQZ Biotechnologies Company falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 64 | 144 | 170 | 98 |
Receivables | NA | 0 | 3 | 2 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 4 | 5 | 2 |
Total Current Assets | NA | 68 | 151 | 177 | 102 |
Net Property & Equipment | NA | 2 | 3 | 4 | 5 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 2 |
Total Assets | NA | 100 | 226 | 231 | 152 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 4 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 7 | 7 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 13 | 26 | 19 |
Total Current Liabilities | NA | 22 | 33 | 45 | 38 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 9 | 20 | 22 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 43 | 102 | 104 | 94 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 132 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 332 | 319 | 254 | 3 |
Retained Earnings | NA | -275 | -196 | -127 | -76 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 57 | 124 | 127 | 59 |
Total Liabilities & Shareholder's Equity | NA | 100 | 226 | 231 | 152 |
Total Common Equity | 0 | 57 | 124 | 127 | -74 |
Shares Outstanding | 29.40 | 29.40 | 28.00 | 24.70 | NA |
Book Value Per Share | 0.00 | 1.94 | 4.43 | 5.15 | 0.00 |
Fiscal Year End for SQZ Biotechnologies Company falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 10 | 25 |
Receivables | NA | NA | NA | 0 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 0 | 0 |
Other Current Assets | NA | NA | NA | 2 | 3 |
Total Current Assets | NA | NA | NA | 12 | 28 |
Net Property & Equipment | NA | NA | NA | 1 | 2 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 0 | 0 |
Deposits & Other Assets | NA | NA | NA | 2 | 2 |
Total Assets | NA | NA | NA | 30 | 54 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | 0 |
Accounts Payable | NA | NA | NA | 2 | 2 |
Current Portion Long-Term Debt | NA | NA | NA | 0 | 0 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 5 | 5 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 0 | 1 |
Total Current Liabilities | NA | NA | NA | 9 | 10 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 0 | 0 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 0 | 0 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 28 | 30 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 0 | 0 |
Capital Surplus | NA | NA | NA | 335 | 334 |
Retained Earnings | NA | NA | NA | -333 | -309 |
Other Equity | NA | NA | NA | 0 | 0 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | 2 | 25 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 30 | 54 |
Total Common Equity | 0 | 0 | 0 | 2 | 25 |
Shares Outstanding | 29.40 | 29.40 | 29.40 | 29.40 | 29.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.06 | 0.83 |